Metagenomi Therapeutics, Inc.
NASDAQMetagenomi Therapeutics reports Q1 2026 results today with a stock down 13% year-to-date, a short score in the 70th percentile, and a history of punishing moves after every print. The lending market tells a story of rising short-side conviction. Short interest has climbed steadily over the past two weeks to roughly 5% of the free float — after a sharper pullback through April — and…
Snapshot as of 25 Jun 2026
Metagenomi Therapeutics reports Q1 2026 results today with a stock down 13% year-to-date, a short score in the 70th percentile, and a history of punishing moves after every print. The lending market tells a story of…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MGX — free to start on ORTEX.
Sign up for free →Open MGX on ORTEX